Nishadil
Signup Signin
Delhi | 25°C (windy)
The Next Battleground: Novo Nordisk and Eli Lilly's Hundred-Year War for Oral GLP-1 Dominance

The Next Battleground: Novo Nordisk and Eli Lilly's Hundred-Year War for Oral GLP-1 Dominance
Metsera: The New Power Player Set to Disrupt the $100 Billion GLP-1 Market

Metsera: The New Power Player Set to Disrupt the $100 Billion GLP-1 Market
Unearthing Tomorrow's Titans: Two Beaten-Down Growth Stocks Primed for Explosive Gains

Unearthing Tomorrow's Titans: Two Beaten-Down Growth Stocks Primed for Explosive Gains
The Weighty Truth: Are Next-Gen Obesity Drugs Worth Their Premium Price Tag?

The Weighty Truth: Are Next-Gen Obesity Drugs Worth Their Premium Price Tag?
Wall Street Roars: Tech Titans, Crypto Currents, and Pharma Shakes Up Tuesday's Trading!

Wall Street Roars: Tech Titans, Crypto Currents, and Pharma Shakes Up Tuesday's Trading!
Viking Therapeutics' Oral Weight Loss Drug Stumbles: VK2735 Data Leaves Investors Underwhelmed

Viking Therapeutics' Oral Weight Loss Drug Stumbles: VK2735 Data Leaves Investors Underwhelmed
Load more..